Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Neal Katz

Neal Katz

Director of Solutions Marketing

Connect with Neal Katz on LinkedIn
Website:

About the author: Neal Katz has over 20 years of experience bringing information technology solutions to market. As Senior Manager of Solutions Marketing at Elsevier, Neal has been responsible for assembling information solutions for life science companies, as well as academic and government institutions. He has developed similar solutions and programs at companies like AT&T and Intel.

Posts by Neal Katz

Predicting Adverse Event Risks and Gaining Insights from Disparate Data

Posted on May 17th, 2017 in Pharma R&D

The upcoming Bio IT World Conference and Expo will feature two talks from Elsevier Life Sciences consultants, focusing on predicting adverse events in clinical trials and extracting knowledge from multiple data sets. (more…)

Easing the Pain in Monitoring Literature for Adverse Drug Events

Posted on September 20th, 2016 in Pharmacovigilance

Over the past year, we have heard about the various challenges associated with the cumbersome task of monitoring scientific literature for adverse drug events (AE) from thought leaders on this blog. Pharmacovigilance professionals have written about the literature monitoring and review process, the recent EMA Medical Literature Monitoring initiative, and the importance of literature search strategies. (more…)

PV Poll: Using Text Mining in Literature Surveillance

Posted on June 14th, 2016 in Pharmacovigilance

We have spoken to several pharmacovigilance teams that are looking into using text mining tools as part of their literature monitoring process.   (more…)

PV Poll: Processing of EMA MLM Data

Posted on March 16th, 2016 in Pharmacovigilance

Over the past few months, we have posted blog entries about the EMA Medical Literature Monitoring (MLM) program, including a review of the EMA Annual Update and impressions of the launch phase closure report. (more…)

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5